A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
Conditions: Microsatellite High Cancers; Peritoneal Mesothelioma; Extrapulmonary High Grade; Neuroendocrine Carcinomas; Cervical Carcinoma; Hodgkin's Lymphoma; Pleural Mesothelioma; Small Cell Lung Cancer Intervention: Drug: XmAb20717 Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Brain | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Lymphoma | Mesothelioma | Neurology | Research